Canada-Approved Medicine
This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canadas Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.
REMSContraindicated in:
Use Cautiously in:
Exercise Extreme Caution in:
CNS: dizziness, drowsiness, fatigue, headache, insomnia, vertigo, weakness.
Resp: cough, dyspnea.
CV: hypotension, chest pain, edema, tachycardia.
Endo: hyperuricemia.
GI: taste disturbances, abdominal pain, anorexia, constipation, diarrhea, nausea, vomiting.
GU: erectile dysfunction, proteinuria, renal dysfunction, renal failure.
Derm: flushing, pruritis, rashes.
F and E: hyperkalemia.
Hemat: AGRANULOCYTOSIS.
MS: back pain, muscle cramps, myalgia.
Misc: ANGIOEDEMA, fever.
Drug-Drug:
Hypertension
Renal Impairment
Hepatic Impairment
Heart Failure
Renal Impairment
Absorption: Well absorbed following oral administration, rapidly converted to active metabolite, cilazaprilat (57% bioavailability for cilazaprilat).
Distribution: Enters breast milk.
Metabolism/Excretion: Cilazaprilat is eliminated unchanged by the kidneys (91%).
Half-life: Early elimination phase 0.9 hr; terminal elimination phase (enzymebound cilazaprilat) 3649 hr.
(effects on hemodynamics)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO (hypertension) | within 1 hr | 37 hr | 1224 hr |
PO (heart failure) | 12 hr | 24 hr | 24 hr |